200
Participants
Start Date
September 30, 2024
Primary Completion Date
April 30, 2025
Study Completion Date
January 30, 2026
HB0017
300mg Q12W
HB0017
300mg Q8W
HB0017
150mg Q4W
RECRUITING
The First Affiliated Hospital of Bengbu Medical College, Bengbu
RECRUITING
Southern Medical University Dermatology Hospital, Guangzhou
RECRUITING
Xiangya Hospital of Central South University, Changsha
RECRUITING
Wuxi Second People's Hospital, Wuxi
RECRUITING
Jiangsu University Affiliated Hospital, Zhenjiang
RECRUITING
Jilin University Second Hospital, Changchun
RECRUITING
Shanxi Medical University Second Hospital, Taiyuan
RECRUITING
Sichuan Provincial People's Hospital, Chengdu
RECRUITING
Chongqing Traditional Chinese Medicine Hospital, Chongqing
RECRUITING
Hangzhou First People's Hospital, Hangzhou
RECRUITING
The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
RECRUITING
Jiaxing First Hospital, Jiaxing
RECRUITING
Wenzhou Medical University Affiliated First Hospital, Wenzhou
RECRUITING
Guangdong Provincial People's Hospital, Guangzhou
RECRUITING
Ningbo Second Hospital, Ningbo
NOT_YET_RECRUITING
Shandong First Medical University Affiliated Dermatology Hospital, Jinan
RECRUITING
Jining First People's Hospital, Jining
RECRUITING
Xingtai People's Hospital, Xingtai
Lead Sponsor
Huabo Biopharm Co., Ltd.
INDUSTRY